Scott Lish Sells 17,857 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Key Points

• Alphatec COO Scott Lish sold 17,857 shares of the company stock for a total of $249,998, reducing his ownership by 2.52%.
• The company's stock recently reached a 52-week high of $15.34 with a significant trading volume of 5,877,914 shares.
• Alphatec reported a quarterly revenue of $185.54 million, surpassing analyst expectations, and projected -1.08 earnings per share for the year.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) COO Scott Lish sold 17,857 shares of Alphatec stock in a transaction that occurred on Monday, August 4th. The stock was sold at an average price of $14.00, for a total transaction of $249,998.00. Following the completion of the sale, the chief operating officer directly owned 690,998 shares of the company's stock, valued at $9,673,972. The trade was a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Scott Lish also recently made the following trade(s):

• On Tuesday, August 5th, Scott Lish sold 16,666 shares of Alphatec stock. The shares were sold at an average price of $15.00, for a total transaction of $249,990.00.
• On Friday, August 1st, Scott Lish sold 36,081 shares of Alphatec stock. The shares were sold at an average price of $12.53, for a total transaction of $452,094.93.
• On Thursday, July 10th, Scott Lish sold 3,982 shares of Alphatec stock. The shares were sold at an average price of $12.00, for a total transaction of $47,784.00.
• On Friday, June 13th, Scott Lish sold 22,727 shares of Alphatec stock. The shares were sold at an average price of $11.07, for a total transaction of $251,587.89.
• On Monday, May 19th, Scott Lish sold 55,375 shares of Alphatec stock. The shares were sold at an average price of $13.00, for a total transaction of $719,875.00.

Alphatec Stock Performance

ATEC traded down $0.30 on Thursday, hitting $14.90. 4,026,655 shares of the company's stock were exchanged, compared to its average volume of 2,076,670. The firm has a market cap of $2.20 billion, a PE ratio of -13.19 and a beta of 1.05. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $15.46. The stock has a fifty day moving average of $11.53 and a two-hundred day moving average of $11.23. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.08. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. The firm had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. During the same quarter in the prior year, the firm earned ($0.29) EPS. Alphatec's quarterly revenue was up 27.5% on a year-over-year basis. On average, research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ATEC shares. Lake Street Capital upgraded shares of Alphatec to a "buy" rating and set a $18.00 target price on the stock in a report on Monday, June 16th. Canaccord Genuity Group reiterated a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a report on Friday, August 1st. Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price objective on shares of Alphatec in a report on Friday, May 2nd. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a report on Monday, April 14th. Finally, Barclays restated an "overweight" rating and issued a $22.00 target price (up previously from $21.00) on shares of Alphatec in a research note on Monday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Alphatec presently has an average rating of "Moderate Buy" and a consensus target price of $18.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ATEC. Comerica Bank boosted its holdings in Alphatec by 66.8% during the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock worth $29,000 after buying an additional 1,248 shares in the last quarter. Quarry LP boosted its holdings in Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock worth $49,000 after buying an additional 2,375 shares in the last quarter. Larson Financial Group LLC bought a new stake in Alphatec during the first quarter worth approximately $54,000. Nisa Investment Advisors LLC boosted its holdings in Alphatec by 22.4% during the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company's stock worth $63,000 after buying an additional 1,045 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new stake in Alphatec during the fourth quarter worth approximately $76,000. 66.35% of the stock is currently owned by institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.